Skip to main content
Figure 4 | Breast Cancer Research

Figure 4

From: Lapatinib–induced NF-kappaB activation sensitizes triple-negative breast cancer cells to proteasome inhibitors

Figure 4

SFK activation contributes to induction of NF-κB by lapatinib. (A) Whole cell lysates of SkBr3, BT474, MDA-MB-231 and their lapatinib-selected clones were collected followed by Western blot analysis with anti-phospho-SFK and anti-tubulin antibodies. (B) SkBr3 and MDA-MB-231 cells were treated with lapatinib for the indicated time points. Phosphorylation of p-SFK and p-IκBα as well as IκBα and tubulin protein expression were detected by Western blot analysis. (C) Whole cell lysates from SkBr3, MDA-MB-231 cells and their lapatinib-treated clones were harvested and subjected to Western blot analysis with specific antibodies for phosphorylation and/or expression of SFK and IκBα. (D) SkBr3, BT474, MDA-MB-231 and their lapatinib-selected clones were treated with the SFK inhibitors, dasatinib (Dasa) or AZD0530 (AZD). Total lysates were prepared and subjected to Western blot analysis with anti-phospho-p65 (Ser536), anti-phospho-SFK and anti-tubulin antibodies. (E) IκBα protein from total lysates of MDA-MB-231 and 231/Lap cells was immunoprecipitated followed by Western blot analysis with anti-p65 antibody for IκBα/p65 protein interaction. SFK, Src family kinase.

Back to article page